ABOUT US

Our Story

Dione Antibiotics, Inc. is an early-stage biopharmaceutical company uniquely positioned to develop a fundamentally new class of proprietary small molecule, non-traditional, direct acting antibiotics against a new drug target to treat drug-resistant 'superbug' bacterial infections. Our approach is driven by innovation and dedication to addressing the urgent global need for effective antibiotics. We are committed to advancing the field of antibiotic research and development to combat the growing threat of antimicrobial resistance.

Born from Innovation at Stanford University

Dione Antibiotics traces its scientific origins to the lab of a Nobel Laureate Scientist. We are dedicated to discovering, developing, and commercializing a novel, direct acting, non-traditional class of antibiotics to combat drug-resistant “superbug” infections caused by antimicrobial resistance (AMR).

Our Breakthrough Approach

Antimicrobial resistance (AMR) is one of the most urgent and escalating threats to global public health. As traditional antibiotics lose effectiveness, the need for novel therapies has never been more critical.

Dione Antibiotics is meeting this challenge head-on with a bold, discovery-stage program built on three key innovations:

A Novel Drug Target
- We target a previously untapped enzyme essential for bacterial survival and pathogenesis in AMR pathogens.
- A first-in-class target not addressed by any currently approved antibiotics.

First-in-Class, Proprietary Compounds
- Our proprietary small molecules are specific inhibitors.
- Represent a new class of antibiotics with no FDA or EMA-approved analogs.

A Unique Mechanism of Action
- Disrupts critical bacterial functions that are not targeted by existing antibiotics.
- A differentiated and resistance-evading strategy to treat even the most resilient superbugs.